<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22457005</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1437-160X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>33</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Rheumatology international</Title>
                <ISOAbbreviation>Rheumatol Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TLR3-mediated apoptosis and activation of phosphorylated Akt in the salivary gland epithelial cells of primary Sjögren's syndrome patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>441-50</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-012-2381-9</ELocationID>
            <Abstract>
                <AbstractText>This study aimed at ascertain whether innate immunity is involved in the apoptosis of primary cultured salivary gland epithelial cells (SGECs) in primary Sjögren's syndrome (pSS). Induction of apoptosis of SGECs was performed using a TLR3 ligand, poly (I:C). Activation of phosphorylated-Akt (pAkt) and cleaved-caspase 3 was determined by Western blotting or immunofluorescence. Expression of TLR2 and TLR3 with pAkt was observed in cultured SGECs after 24-h stimulation with each ligand. Compared with stimulation with the peptidoglycan or lipopolysaccharide, that with poly (I:C) induced significant nuclear fragmentation, as determined by Hoechst staining (p = 0.0098). Apoptosis was confirmed by terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL) staining of SGECs from pSS patients and a normal subject. A significant increase in TUNEL-positive cells was observed by the addition of a PI3K inhibitor, LY294002. Poly (I:C) phosphorylated stress-activated protein kinase/Jun-terminal kinase and p44/42 MAP kinase as well as Akt. Furthermore, poly (I:C)-induced caspase 3 cleavage in SGECs was also inhibited by LY294002. Similar results were obtained using SGECs obtained from a normal subject. The results demonstrated for the first time that TLR3 induces the apoptotic cell death of SGECs via the PI3K-Akt signaling pathway.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nakamura</LastName>
                    <ForeName>Hideki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki 852-8501, Japan. nhideki@nagasaki-u.ac.jp</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Horai</LastName>
                    <ForeName>Yoshiro</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Takahisa</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okada</LastName>
                    <ForeName>Akitomo</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ichinose</LastName>
                    <ForeName>Kunihiro</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamasaki</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koji</LastName>
                    <ForeName>Takehiko</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawakami</LastName>
                    <ForeName>Atsushi</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>03</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Rheumatol Int</MedlineTA>
            <NlmUniqueID>8206885</NlmUniqueID>
            <ISSNLinking>0172-8172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C495344">TLR3 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051196">Toll-Like Receptor 3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.24</RegistryNumber>
                <NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.22.-</RegistryNumber>
                <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>O84C90HH2L</RegistryNumber>
                <NameOfSubstance UI="D011070">Poly I-C</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011070" MajorTopicYN="N">Poly I-C</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012469" MajorTopicYN="N">Salivary Glands</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012859" MajorTopicYN="N">Sjogren's Syndrome</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051196" MajorTopicYN="N">Toll-Like Receptor 3</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>03</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22457005</ArticleId>
            <ArticleId IdType="doi">10.1007/s00296-012-2381-9</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 2005 Jul 23-29;366(9482):321-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16039337</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Immunol. 2010 May;11(5):373-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20404851</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Apoptosis. 2008 Nov;13(11):1322-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18791828</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cell Biochem. 2007 Apr 1;100(5):1301-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17243100</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Rheumatology (Oxford). 2010 Jul;49(7):1290-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20338890</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Autoimmun. 2010 Nov;35(3):212-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20685081</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Musculoskelet Disord. 2010 Jul 01;11:140</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20591195</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Rheumatol. 2007 Nov-Dec;25(6):831-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18173916</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Rheum Dis. 2002 Jun;61(6):554-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12006334</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Immunol. 2004 May;5(5):503-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15064760</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Rheumatol. 2007 May;34(5):1019-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17407216</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell. 2010 Mar 19;140(6):805-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20303872</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3336-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18660424</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Struct Mol Biol. 2004 Nov;11(11):1060-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15502848</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Top Microbiol Immunol. 2006;311:1-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17048703</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lab Invest. 2001 Jan;81(1):95-105</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11204278</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Autoimmun. 1999 Aug;13(1):155-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10441181</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2003 Aug 1;301(5633):640-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12855817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2006 May 30;103(22):8459-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16714379</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2011 Jul 1;187(1):510-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21646299</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arthritis Rheum. 1997 Jan;40(1):87-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9008604</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2004 Mar 18;428(6980):341-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15029200</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 2006 Apr 15;176(8):4894-901</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16585585</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Transl Res. 2006 Dec;148(6):281-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17162248</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Rheumatol. 1998 Sep-Oct;16(5):561-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9779303</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Immunol. 2005 Jun;5(6):446-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15928677</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Adv Exp Med Biol. 1994;350:637-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8030547</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Immunol. 1998 Oct;114(1):106-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9764611</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
